Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy

H. C. Jeung, S. Y. Rha, W. I. Jang, S. H. Noh, H. C. Chung

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: The treatment options for the 10-20 per cent of patients with gastric cancer who present with peritoneal dissemination are extremely limited and no standard approach exists. Methods: The feasibility of using intraperitoneal chemotherapy to treat gastric cancer with intraabdominal gross residual lesions after palliative gastrectomy with maximal cytoreduction was investigated. Early postoperative intraperitoneal chemotherapy started on the day of operation with 5-fluorouracil 500 mg/m2 and cisplatin 40 mg/m2 (days 1-3) over a 4-week interval. Results: Of the 53 patients enrolled between July 1994 and December 1998, 49 were eligible. The progression-free survival (PFS) was 7 months and the overall survival was 12 months. In multivariate analysis, performance status was the only significant defining factor for PFS (P = 0.009). The predominant toxicity was neutropenia and nausea/vomiting. The relative dose intensity of 5-florouracil and cisplatin was 89 and 63 per cent respectively. Conclusion: Performance status emerged as a major determining factor for prognosis and patient selection for early postoperative intraperitoneal chemotherapy in patients with advanced gastric cancer after maximally cytoreductive surgery.

Original languageEnglish
Pages (from-to)460-466
Number of pages7
JournalBritish Journal of Surgery
Volume89
Issue number4
DOIs
Publication statusPublished - 2002 Jun 17

Fingerprint

Gastrectomy
Stomach Neoplasms
Drug Therapy
Cisplatin
Disease-Free Survival
Neutropenia
Fluorouracil
Nausea
Patient Selection
Vomiting
Therapeutics
Multivariate Analysis
Survival

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

@article{41ed3c811873474a8bb458807ed5d651,
title = "Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy",
abstract = "Background: The treatment options for the 10-20 per cent of patients with gastric cancer who present with peritoneal dissemination are extremely limited and no standard approach exists. Methods: The feasibility of using intraperitoneal chemotherapy to treat gastric cancer with intraabdominal gross residual lesions after palliative gastrectomy with maximal cytoreduction was investigated. Early postoperative intraperitoneal chemotherapy started on the day of operation with 5-fluorouracil 500 mg/m2 and cisplatin 40 mg/m2 (days 1-3) over a 4-week interval. Results: Of the 53 patients enrolled between July 1994 and December 1998, 49 were eligible. The progression-free survival (PFS) was 7 months and the overall survival was 12 months. In multivariate analysis, performance status was the only significant defining factor for PFS (P = 0.009). The predominant toxicity was neutropenia and nausea/vomiting. The relative dose intensity of 5-florouracil and cisplatin was 89 and 63 per cent respectively. Conclusion: Performance status emerged as a major determining factor for prognosis and patient selection for early postoperative intraperitoneal chemotherapy in patients with advanced gastric cancer after maximally cytoreductive surgery.",
author = "Jeung, {H. C.} and Rha, {S. Y.} and Jang, {W. I.} and Noh, {S. H.} and Chung, {H. C.}",
year = "2002",
month = "6",
day = "17",
doi = "10.1046/j.0007-1323.2001.02048.x",
language = "English",
volume = "89",
pages = "460--466",
journal = "British Journal of Surgery",
issn = "0007-1323",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy. / Jeung, H. C.; Rha, S. Y.; Jang, W. I.; Noh, S. H.; Chung, H. C.

In: British Journal of Surgery, Vol. 89, No. 4, 17.06.2002, p. 460-466.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy

AU - Jeung, H. C.

AU - Rha, S. Y.

AU - Jang, W. I.

AU - Noh, S. H.

AU - Chung, H. C.

PY - 2002/6/17

Y1 - 2002/6/17

N2 - Background: The treatment options for the 10-20 per cent of patients with gastric cancer who present with peritoneal dissemination are extremely limited and no standard approach exists. Methods: The feasibility of using intraperitoneal chemotherapy to treat gastric cancer with intraabdominal gross residual lesions after palliative gastrectomy with maximal cytoreduction was investigated. Early postoperative intraperitoneal chemotherapy started on the day of operation with 5-fluorouracil 500 mg/m2 and cisplatin 40 mg/m2 (days 1-3) over a 4-week interval. Results: Of the 53 patients enrolled between July 1994 and December 1998, 49 were eligible. The progression-free survival (PFS) was 7 months and the overall survival was 12 months. In multivariate analysis, performance status was the only significant defining factor for PFS (P = 0.009). The predominant toxicity was neutropenia and nausea/vomiting. The relative dose intensity of 5-florouracil and cisplatin was 89 and 63 per cent respectively. Conclusion: Performance status emerged as a major determining factor for prognosis and patient selection for early postoperative intraperitoneal chemotherapy in patients with advanced gastric cancer after maximally cytoreductive surgery.

AB - Background: The treatment options for the 10-20 per cent of patients with gastric cancer who present with peritoneal dissemination are extremely limited and no standard approach exists. Methods: The feasibility of using intraperitoneal chemotherapy to treat gastric cancer with intraabdominal gross residual lesions after palliative gastrectomy with maximal cytoreduction was investigated. Early postoperative intraperitoneal chemotherapy started on the day of operation with 5-fluorouracil 500 mg/m2 and cisplatin 40 mg/m2 (days 1-3) over a 4-week interval. Results: Of the 53 patients enrolled between July 1994 and December 1998, 49 were eligible. The progression-free survival (PFS) was 7 months and the overall survival was 12 months. In multivariate analysis, performance status was the only significant defining factor for PFS (P = 0.009). The predominant toxicity was neutropenia and nausea/vomiting. The relative dose intensity of 5-florouracil and cisplatin was 89 and 63 per cent respectively. Conclusion: Performance status emerged as a major determining factor for prognosis and patient selection for early postoperative intraperitoneal chemotherapy in patients with advanced gastric cancer after maximally cytoreductive surgery.

UR - http://www.scopus.com/inward/record.url?scp=0036274459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036274459&partnerID=8YFLogxK

U2 - 10.1046/j.0007-1323.2001.02048.x

DO - 10.1046/j.0007-1323.2001.02048.x

M3 - Article

C2 - 11952588

AN - SCOPUS:0036274459

VL - 89

SP - 460

EP - 466

JO - British Journal of Surgery

JF - British Journal of Surgery

SN - 0007-1323

IS - 4

ER -